Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD14-01 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT05444322Phase 1Unknown
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD14-01 in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Primary endpoints: Dose-limiting toxicity up to 2 years and Maximum tolerable dose up to 2 years. Status: unknown.
02
Drugs
RD14-01
03
Conditions
mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05444322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444322.